REHOVOT, Israel and JERSEY CITY, New Jersey, August 19 /PRNewswire/ --
- Key Milestone Achieved With First Diagnostic Test Based on Company's microRNA Technology, Developed by Columbia University Medical Center, Approved for Clinical use
- Acquires CLIA-certified lab to Expedite Commercialization of its microRNA-based Tests
- Expands Pipeline With Three Additional microRNA-based Cancer Tests in Development
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based diagnostic and therapeutic products, reported today its consolidated financial results for the quarter ended June 30, 2008 and business highlights.